Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Veda Prachayasittikul, Prasit Mandi, Supaluk Prachayasittikul, Somsak Ruchirawat, Virapong Prachayasittikul
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.3322/caac.21820
10.3322/caac.21820
10.3322/caac.21834
10.3322/caac.21834
Unveiling the mechanisms and challenges of cancer drug resistance
10.1186/s12964-023-01302-1 · 2024
Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics
2023
Historical perspective and current trends in anticancer drug development
10.3390/cancers16101878 · 2024
Redox ticklers and beyond: naphthoquinone repository in the spotlight against inflammation and associated maladies
10.1016/j.phrs.2021.105968 · 2021
1,4-naphthoquinones: some biological properties and application
10.1248/cpb.c19-00911 · 2020
Unlocking the potential of 1,4-naphthoquinones: a comprehensive review of their anticancer properties
10.1016/j.ejmech.2024.116249 · 2024
Design, synthesis, and cytotoxic activity of 2-amino-1,4-naphthoquinone-benzamide derivatives as apoptosis inducers
10.1038/s41598-024-78468-2 · 2024
2,3-diaminonaphthalene-1,4-dione: versatile precursor for the synthesis of molecular systems
10.1080/00397911.2024.2435467 · 2025
In vitro and in vivo biological evaluation of novel 1,4-naphthoquinone derivatives as potential anticancer agents
10.1002/cmdc.202400495 · 2024
Design, synthesis and pharmacological evaluation of 1,4-naphthoquinone- 1,2,3-triazole hybrids as new anticancer agents with multi-kinase inhibitory activity
10.1038/s41598-025-87483-w · 2025
Novel naphthoquinones as potent aromatase inhibitors: synthesis, anticancer, and in silico studies
10.1016/j.molstruc.2024.138981 · 2024
1,4-naphthoquinone thiazoles: synthesis, crystal structure, anti-proliferative activity, and inverse molecular docking study
10.1016/j.molstruc.2024.140330 · 2025
Naphthoquinones and derivatives as potential anticancer agents: an updated review
10.1016/j.cbi.2022.110198 · 2022
Doxorubicin-induced cardiotoxicity and risk factors
2024
Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance
10.1177/1078155219877931 · 2020
10.1111/cts.12980
10.1111/cts.12980
10.1016/j.apsb.2022.02.002
10.1016/j.apsb.2022.02.002
10.1016/j.ejmech.2021.113705
10.1016/j.ejmech.2021.113705
10.1016/j.imu.2022.100880
10.1016/j.imu.2022.100880
The trends and future prospective of in silico models from the viewpoint of adme evaluation in drug discovery
10.3390/pharmaceutics15112619 · 2023
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery
10.1016/j.bmc.2022.116614 · 2022
10.1080/17460441.2016.1272757
10.1080/17460441.2016.1272757
Unresolved referenced work
2021
Recent advances in machine-learning-based chemoinformatics: a comprehensive review
10.3390/ijms241411488 · 2023
Aromatase inhibitory activity of 1,4-naphthoquinone derivatives and qsar study
2017
Discovery of novel 1,2,3-triazole derivatives as anticancer agents using qsar and in silico structural modification
10.1186/s40064-015-1352-5 · 2015
10.1021/acsomega.1c04552
10.1021/acsomega.1c04552
Qsar-driven rational design of novel dna methyltransferase 1 inhibitors
2020
Rational design of novel coumarins: a potential trend for antioxidants in cosmetics
2020
Rational design of novel sirtuin 1 activators via structure-activity insights from application of qsar modeling
2019
10.1016/j.ejmech.2015.09.001
10.1016/j.ejmech.2015.09.001
Anti-cancer activities of 1, 4-naphthoquinones: a QSAR study
10.2174/187152006778226512 · 2006
QSAR on antiproliferative naphthoquinones based on a conformation-independent approach
10.1016/j.ejmech.2014.02.057 · 2014
Synthesis, anti-proliferative activity evaluation and 3D-QSAR study of naphthoquinone derivatives as potential anti-colorectal cancer agents
10.3390/molecules23010186 · 2018
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity
1987
10.1016/0022-1759(83)90303-4
10.1016/0022-1759(83)90303-4
Unresolved referenced work
1997
Unresolved referenced work
2003
10.1093/nar/gkr320
10.1093/nar/gkr320 · doi-reference
A measure of domain of applicability for QSAR modelling based on intelligent k-means clustering
10.1002/qsar.200630086 · doi-reference
10.1007/978-1-4939-7899-1_6
10.1007/978-1-4939-7899-1_6 · doi-reference
Basic validation procedures for regression models in QSAR and QSPR studies: theory and application
10.1590/s0103-50532009000400021 · doi-reference
Principles of qsar models validation: internal and external
10.1002/qsar.200610151 · doi-reference
10.1021/ci0342472
10.1021/ci0342472 · doi-reference
Assessing model fit by cross-validation
10.1021/ci025626i · doi-reference
Benchmarking small-dataset structure-activity-relationship models for prediction of Wnt signaling inhibition
10.1109/access.2020.3046190 · doi-reference
A review of quantitative structure-activity relationship: the development and current status of data sets, molecular descriptors and mathematical models
10.1016/j.chemolab.2024.105278 · doi-reference
10.1002/cam4.2678
10.1002/cam4.2678 · doi-reference
10.1038/cr.2008.30
10.1038/cr.2008.30 · doi-reference
Targeting monoamine oxidase a: a strategy for inhibiting tumor growth with both immune checkpoint inhibitors and immune modulators
10.1007/s00262-023-03622-0 · doi-reference
Inflammation in cancer: therapeutic opportunities from new insights
10.1186/s12943-025-02243-8 · doi-reference
Toll-like receptor 9 agonists in cancer
10.2147/ott.s247050 · doi-reference
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
10.1038/s41698-023-00364-1 · doi-reference
10.3390/cells14070488
10.3390/cells14070488 · doi-reference
10.1016/j.medidd.2022.100122
10.1016/j.medidd.2022.100122 · doi-reference
Synthesis, biological activity and docking calculations of bis-naphthoquinone derivatives from lawsone
10.1016/j.bioorg.2021.105069 · doi-reference
Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources
10.3389/fphar.2022.1046818 · doi-reference
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors
10.1021/jm7014155 · doi-reference
10.1016/j.bbrc.2013.04.044
10.1016/j.bbrc.2013.04.044 · doi-reference
Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and CDC25
10.1016/j.ejmech.2019.111719 · doi-reference
Plumbagin suppresses pulmonary fibrosis via inhibition of p300 histone acetyltransferase activity
10.1089/jmf.2019.4670 · doi-reference
Anticancer effects and mechanisms of action of plumbagin: review of research advances
10.1155/2020/6940953 · doi-reference
New naphthoquinone thiazole hybrids as carbonic anhydrase and cholinesterase inhibitors: synthesis, crystal structure, molecular docking, and acid dissociation constant
10.1016/j.molstruc.2023.137365 · doi-reference
10.3390/metabo10100412
10.3390/metabo10100412 · doi-reference
10.1016/j.tips.2017.11.007
10.1016/j.tips.2017.11.007 · doi-reference
10.1038/cmi.2017.143
10.1038/cmi.2017.143 · doi-reference
IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma
10.1038/s41419-022-05021-2 · doi-reference
10.1186/s13045-021-01080-8
10.1186/s13045-021-01080-8 · doi-reference
Characteristics of anticancer activity of CBP/p300 inhibitors – features of their classes, intracellular targets and future perspectives of their application in cancer treatment
10.1016/j.pharmthera.2024.108636 · doi-reference
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
10.1038/s41420-024-01940-5 · doi-reference
In silico analysis reveals EP300 as a pancancer inhibitor of anti-tumor immune response via metabolic modulation
10.1038/s41598-020-66329-7 · doi-reference
10.3390/cancers15041219
10.3390/cancers15041219 · doi-reference
10.1016/j.biopha.2024.116130
10.1016/j.biopha.2024.116130 · doi-reference
10.3390/biom13030417
10.3390/biom13030417 · doi-reference
10.1021/cr500452k
10.1021/cr500452k · doi-reference
10.7150/thno.73223
10.7150/thno.73223 · doi-reference
10.1186/s12943-025-02269-y
10.1186/s12943-025-02269-y · doi-reference
10.1002/cac2.12374
10.1002/cac2.12374 · doi-reference